Trade Names:GamaSTAN S/D- Injection, solution 15% to 18% proteinGamaSTAN S/D (Canada)
Replaces normal human immunoglobulin (Ig) G antibodies.
The elimination half-life is approximately 23 days.
Approximately 2 days.
Prophylaxis of hepatitis A; prevention or modification of measles in persons exposed fewer than 6 days previously (children older than 12 mo of age who have received GamaSTAN S/D should be given measles vaccine about 3 mo later when the measles antibody titer will have disappeared); passive immunization against varicella in immunosuppressed patients; prophylaxis of rubella in pregnancy when therapeutic abortion is not an option; prevention of serious infection in patients with IgG deficiencies.
Persons with isolated IgA deficiency; patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate IM injections.
IM 0.02 mL/kg (0.01 mL/lb) for household and institutional hepatitis A case contacts.For persons who plan to travel to areas where hepatitis is common
Administer 0.02 mL/kg if length of stay is less than 3 mo, and 0.06 mL/kg, repeated every 4 to 6 mo, if length of stay is 3 mo or longer.IgG DeficiencyAdults and Children
IM 0.66 mL/kg (at least 100 mg/kg) every 3 to 4 wk; some patients may require more frequent injections. Administer a double dose at onset of therapy.Postexposure Measles ProphylaxisAdults and Children
IM 0.25 mL/kg (0.11 mL/lb). To prevent or modify measles in susceptible persons exposed fewer than 6 days previously.Susceptible Immunocompromised Children
IM 0.5 mL/kg (max, 15 mL).Postexposure Varicella ProphylaxisAdults and Children
IM 0.6 to 1.2 mL/kg (if varicella-zoster immune globulin is unavailable).RubellaAdults and Children
IM 0.55 mL/kg may benefit women who will not consider a therapeutic abortion.
Store vials in refrigerator (36° to 46°F). Do not freeze.
To avoid inactivating vaccines containing live viruses or bacteria, give live vaccines approximately 3 mo after immune globulin IM, depending on dose.
None well documented.
Anaphylactic reactions (rare), angioedema, local pain and tenderness at injection site, urticaria.
Category C .
Safety and efficacy not established.
Hypersensitivity, including anaphylaxis, may occur. Administer drug with caution in patients with prior systemic allergic reactions to human immunoglobulins.
Administer with caution to persons receiving anticoagulant therapy because of IM administration.
Immune globulin is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease.
Copyright © 2009 Wolters Kluwer Health.